Geron Corp. (NASDAQ: GERN), a small-cap cancer company, released its fourth-quarter and full-year earnings after the bell last Friday. While earnings for developmental-stage biotechs like Geron are generally meaningless, the company did update investors on the progress of the collaboration with Johnson & Johnson's (NYSE: JNJ) biotech subsidiary Janssen. The two companies are presently developing the first-in-class telomerase inhibitor, imetelstat, for a basket of blood-based cancers. Oddly enough, though, Geron decided to bury the most important of these clinical updates deep in the press release, and it also left out another major regulatory update altogether. Image Source: Getty Images.Continue reading